---
title: "TCRX: TSC-101 showed 79% relapse-free survival at 6 months in high-risk post-HCT patients"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297781448.md"
description: "Prioritization is on in vivo TCR-T therapies for solid tumors, with IND-enabling studies progressing and preclinical data expected in early 2027. In the heme program, TSC-101 showed promising relapse-free survival and safety in high-risk post-HCT patients.Original document: TScan Therapeutics, Inc. [TCRX] Slides Release — Sep. 2 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-09-02T11:57:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297781448.md)
  - [en](https://longbridge.com/en/news/297781448.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297781448.md)
generator: "portal-rs"
---

# TCRX: TSC-101 showed 79% relapse-free survival at 6 months in high-risk post-HCT patients

Prioritization is on in vivo TCR-T therapies for solid tumors, with IND-enabling studies progressing and preclinical data expected in early 2027. In the heme program, TSC-101 showed promising relapse-free survival and safety in high-risk post-HCT patients.

Original document: TScan Therapeutics, Inc. \[TCRX\] Slides Release — Sep. 2 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [TCRX.US](https://longbridge.com/en/quote/TCRX.US.md)

## Related News & Research

- [TScan Therapeutics cuts workforce 75% in reorganization to focus on in vivo solid tumor cell therapy](https://longbridge.com/en/news/297773935.md)
- [TCRX: Focus shifts to in vivo TCR-T solid tumor therapies, with two candidates advancing to clinical studies](https://longbridge.com/en/news/297776068.md)
- [TCRX: In vivo TCR therapies for solid tumors advance to IND-enabling stage, with phase I trial set for Q4 2027](https://longbridge.com/en/news/297802700.md)
- [TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction](https://longbridge.com/en/news/297808078.md)
- [Intel (INTC) Stock Looks Above Fair Value After Its 256% Run](https://longbridge.com/en/news/299431661.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**